Literature DB >> 15758023

Imatinib and regression of type 2 diabetes.

Dino Veneri, Massimo Franchini, Enzo Bonora.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15758023     DOI： 10.1056/NEJM200503103521023

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  39 in total

1.  Loss of PDGF-B activity increases hepatic vascular permeability and enhances insulin sensitivity.

Authors:  Summer M Raines; Oliver C Richards; Lindsay R Schneider; Kathryn L Schueler; Mary E Rabaglia; Angie T Oler; Donald S Stapleton; Guillem Genové; John A Dawson; Christer Betsholtz; Alan D Attie
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-06-14       Impact factor: 4.310

2.  Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis.

Authors:  Minglin Lin; Junfei Jin
Journal:  Nat Rev Clin Oncol       Date:  2017-04-19       Impact factor: 66.675

Review 3.  Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Authors:  Laura M Jacobsen; Brittney N Newby; Daniel J Perry; Amanda L Posgai; Michael J Haller; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2018-08-30       Impact factor: 4.810

Review 4.  Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

Authors:  Jeryl Villadolid; Jennifer L Ersek; Mei Ka Fong; Lindsey Sirianno; Ellen S Story
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 5.  Exploring the recent molecular targets for diabetes and associated complications.

Authors:  Amit Gupta; Tapan Behl; Aayush Sehgal; Shaveta Bhardwaj; Sukhbir Singh; Neelam Sharma; Abdul Hafeez
Journal:  Mol Biol Rep       Date:  2021-03-24       Impact factor: 2.316

Review 6.  Clinical review: kinase inhibitors: adverse effects related to the endocrine system.

Authors:  Maya B Lodish
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

7.  PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue.

Authors:  Sun-Sil Choi; Eun-Sun Kim; Ji-Eun Jung; David P Marciano; Ala Jo; Ja Young Koo; Soo Youn Choi; Yong Ryoul Yang; Hyun-Jun Jang; Eung-Kyun Kim; Jiyoung Park; Hyug Moo Kwon; In Hee Lee; Seung Bum Park; Kyung-Jae Myung; Pann-Ghill Suh; Patrick R Griffin; Jang Hyun Choi
Journal:  Diabetes       Date:  2016-01-06       Impact factor: 9.461

8.  Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.

Authors:  M Haap; B Gallwitz; C Thamer; K Müssig; H-U Häring; L Kanz; J T Hartmann
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

Review 9.  Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Authors:  Andrew M Bellinger; Carlos L Arteaga; Thomas Force; Benjamin D Humphreys; George D Demetri; Brian J Druker; Javid J Moslehi
Journal:  Circulation       Date:  2015-12-08       Impact factor: 29.690

10.  EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.

Authors:  Patricia O Prada; Eduardo R Ropelle; Rosa H Mourão; Claudio T de Souza; Jose R Pauli; Dennys E Cintra; André Schenka; Silvana A Rocco; Roberto Rittner; Kleber G Franchini; José Vassallo; Lício A Velloso; José B Carvalheira; Mario J A Saad
Journal:  Diabetes       Date:  2009-08-20       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.